Petros Pharmaceuticals, Inc.
PTPI
$0.0275
-$0.0005-1.79%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.30M | 3.72M | 5.11M | 4.02M | 4.12M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.30M | 3.72M | 5.11M | 4.02M | 4.12M |
| Cost of Revenue | 551.80K | 551.80K | 551.80K | 445.10K | 566.60K |
| Gross Profit | 1.75M | 1.75M | 1.75M | 767.00K | 743.80K |
| SG&A Expenses | 7.01M | 6.56M | 6.60M | 8.03M | 7.73M |
| Depreciation & Amortization | 1.40M | 1.40M | 1.40M | 1.54M | 1.63M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.65M | 9.20M | 9.24M | 11.44M | 11.15M |
| Operating Income | -7.35M | -6.89M | -6.94M | -10.23M | -9.84M |
| Income Before Tax | -14.73M | -12.31M | -10.73M | -1.14M | -3.46M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14.73 | -12.31 | -10.73 | -1.14 | -3.46 |
| Earnings from Discontinued Operations | 6.41M | -2.11M | -3.59M | -3.59M | -3.59M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.32M | -14.42M | -14.32M | -4.73M | -7.06M |
| EBIT | -7.35M | -6.89M | -6.94M | -10.23M | -9.84M |
| EBITDA | -4.53M | -4.07M | -4.11M | -7.25M | -6.78M |
| EPS Basic | -50.69 | -58.66 | -91.47 | -105.16 | -163.08 |
| Normalized Basic EPS | -13.97 | -13.11 | -11.21 | 0.63 | -29.38 |
| EPS Diluted | -50.69 | -58.66 | -91.47 | -105.16 | -163.08 |
| Normalized Diluted EPS | -13.97 | -13.11 | -11.21 | 0.63 | -29.38 |
| Average Basic Shares Outstanding | 27.88M | 2.25M | 1.28M | 974.10K | 665.70K |
| Average Diluted Shares Outstanding | 27.88M | 2.25M | 1.28M | 974.10K | 665.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |